Disclaimer: Testosterone enanthate is a prescription-only medicine in the UK, available legally for the treatment of hypogonadism and other clinical indications. Possession without prescription is not illegal under UK law (it is not a Class C offence), but supply without a licence is. This guide is educational. It is not a protocol recommendation.
Drug Profile
| Parameter | Detail | |-----------|--------| | Drug class | Androgen / anabolic steroid | | Chemical name | Testosterone 17β-enanthate | | Anabolic:Androgenic ratio | 100:100 (reference compound — all other AAS are measured against testosterone) | | Aromatisation | Yes — converts to oestradiol via aromatase enzyme | | 5-alpha reduction | Yes — converts to DHT in target tissues (skin, scalp, prostate) | | Ester | Enanthate (long-chain, 7-carbon) | | Half-life | 4.5–5 days | | Active life | 8–10 days | | Detection time | Up to 3 months (urinary metabolites) | | Route of administration | Intramuscular or subcutaneous injection | | UK legal status | Prescription-only medicine (not a controlled substance) | | Notable brand names | Testosterone Depot (Rotexmedica, Germany); Testobolin (Alpha-Pharma); Testosteron Enantat (various) |
Background and History
Testosterone enanthate was developed in the 1950s as one of the first long-acting injectable testosterone preparations. It was designed to solve the practical limitation of earlier testosterone propionate formulations, which required injections every 2–3 days due to a very short ester.
The enanthate ester, attached to the testosterone molecule at the 17-beta hydroxyl group, forms a prodrug that is slowly hydrolysed in the body to release free testosterone. The rate of hydrolysis is determined by the ester chain length — enanthate's 7-carbon chain produces a half-life of approximately 4.5–5 days, making once or twice weekly dosing practical.
Testosterone enanthate became the dominant pharmaceutical testosterone form across most of Europe and large parts of the world. (Testosterone cypionate — structurally almost identical, with an 8-carbon ester — became the dominant form in the United States.) For clinical purposes, enanthate and cypionate are interchangeable — the clinical profiles, side effects, and monitoring requirements are essentially the same.
Pharmacological Mechanism
Testosterone exerts its effects through multiple pathways:
Direct androgen receptor activation
Testosterone binds the androgen receptor (AR), which translocates to the cell nucleus and acts as a transcription factor — activating or suppressing gene expression. This is the primary mechanism for: protein synthesis stimulation, nitrogen retention, red blood cell stimulation (EPO induction), libido and sexual function, and bone density maintenance.
DHT conversion via 5-alpha reductase
In tissues containing 5-alpha reductase — primarily skin, scalp, prostate, and seminal vesicles — testosterone is converted to dihydrotestosterone (DHT), which has approximately 3× the AR binding affinity of testosterone. DHT mediates the androgenic side effects in these tissues: sebaceous gland activity (acne), male pattern hair loss in genetically predisposed men, and prostate effects.
5-alpha reductase inhibitors (finasteride, dutasteride) block this conversion and reduce androgenic side effects in DHT-sensitive tissues.
Oestradiol conversion via aromatase
In adipose tissue, liver, and muscle, testosterone is converted to oestradiol (E2) by the aromatase enzyme. Oestradiol in men is not an enemy — it is essential for:
- Libido (surprising to many, but the research is clear: oestradiol is required for male libido) [Source: Finkelstein JS et al., 2013 — Gonadal steroids and body composition, strength, and sexual function in men — NEJM, 369:1011–1022]
- Bone density
- Cardiovascular protective effects
- Mood and cognitive function
- Joint lubrication
The problem with oestrogen in TRT is excess — too much oestradiol (relative to the individual's threshold) causes symptoms: water retention, mood disruption, nipple sensitivity, and gynecomastia risk. The goal is maintenance within a functional range, not suppression.
IGF-1 stimulation
Testosterone (and DHT) stimulate hepatic and peripheral production of IGF-1, a potent downstream growth factor. IGF-1 mediates much of testosterone's anabolic effect on muscle tissue.
Clinical Evidence Base
Testosterone enanthate has one of the most robust evidence bases of any AAS compound, precisely because it has been used in clinical medicine for over 70 years.
Hypogonadism treatment
The primary indication. Multiple large randomised trials demonstrate:
- Significant improvements in libido, sexual function, and mood in hypogonadal men [Source: Bhasin S et al., 2001 — Testosterone dose-response relationships in healthy young men — American Journal of Physiology]
- Lean mass increases and fat mass decreases at therapeutic doses [Source: Storer TW et al., 2003 — A randomised, placebo-controlled, dose-response trial of testosterone on lean body mass, strength and power — JCEM]
- Bone mineral density improvement [Source: Snyder PJ et al., 2000 — Effect of testosterone treatment on bone mineral density in men over 65 years of age — JCEM]
- Cardiovascular marker improvement in hypogonadal men (though this is a contested area at higher than therapeutic doses) [Source: Isidori AM et al., 2005 — Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men — Clinical Endocrinology]
The T Trials (Testosterone Trials)
A landmark set of seven trials coordinated by the NIH, published 2016–2017, studying testosterone supplementation in men over 65 with confirmed low testosterone. Key findings:
- Significant improvements in sexual function, desire, and activity [Source: Snyder PJ et al., 2016 — NEJM]
- Significant improvements in walking distance and self-reported vitality
- Improvements in mood and depression symptoms
- Modest increases in bone density
The T Trials provided the most rigorous modern evidence base for testosterone therapy in older men with confirmed deficiency. [Source: Snyder PJ et al., 2016 — Testosterone Trial in Older Men — multiple papers, NEJM, Lancet Diabetes & Endocrinology, etc.]
Therapeutic Dosing: TRT vs. Supraphysiological
TRT / Replacement Doses
For confirmed hypogonadism under medical supervision:
- 100–200mg per week (typically 100mg twice weekly or 200mg once weekly)
- Target: maintain serum testosterone in the mid-to-upper reference range (around 18–30 nmol/L)
- Blood levels should be checked at trough (day before next injection) and at peak (24–48 hours post-injection) to understand the range
The Bhasin Dose-Response Study
The most important pharmacological study of testosterone dose-response effects in men — Bhasin et al. (2001) examined the effects of a range of testosterone doses (25mg to 600mg/week) in healthy young men whose endogenous production was suppressed. Key findings:
- Fat-free mass increased linearly with dose up to 600mg/week
- Strength increased with dose
- Fat mass decreased with dose
- Side effects increased with dose — haematocrit, LDL, and blood pressure effects all worsened with higher doses
This study is foundational for understanding why TRT and supraphysiological dosing are different in their risk profiles. The same compound at 125mg/week (TRT range) and 600mg/week (non-medical bodybuilding range) are not pharmacologically equivalent risk propositions.
[Source: Bhasin S et al., 2001 — Testosterone dose-response relationships in healthy young men — American Journal of Physiology — Endocrinology and Metabolism, 281(6):E1172–81]
Side Effects: The Full Picture
Oestrogen-Related (Dose-Dependent)
Water retention: Oestradiol increases sodium and water retention. At therapeutic TRT doses this is usually minimal. At higher doses, oedema, bloating, and increased blood pressure from fluid retention can occur.
Gynecomastia: Excess oestradiol relative to androgen activity stimulates glandular breast tissue development. In susceptible men, this can occur even at therapeutic doses. Risk is managed by: keeping oestradiol within functional range, avoiding obesity (adipose tissue is a major site of aromatisation), and in some cases low-dose aromatase inhibitor use — though the latter must be used carefully to avoid oestrogen suppression.
Mood and libido changes: Both excessively high and excessively low oestradiol cause mood disruption and libido reduction. Finding the optimal oestradiol range for the individual is one of the key management challenges in TRT. There is no single correct number — symptom-guided management is essential.
Androgenic Effects
Male pattern hair loss: In genetically predisposed men, testosterone (via DHT) accelerates hair loss. This is dose-dependent and cannot be prevented without 5-alpha reductase inhibition (finasteride, dutasteride).
Acne: DHT-mediated sebaceous gland hypertrophy. Usually manageable at TRT doses with standard skincare. Can be more significant at higher doses.
Prostate stimulation: Testosterone does not cause prostate cancer — this was the longstanding medical fear that drove TRT underprescription for decades, and it has been substantially revised by subsequent research. However, testosterone does stimulate PSA and can worsen existing BPH symptoms. PSA should be monitored. [Source: Morgentaler A et al., 2015 — Testosterone therapy and prostate cancer — Endocrine Practice]
Haematological
Erythrocytosis (elevated haematocrit): Testosterone increases EPO production, which drives red blood cell production. Elevated haematocrit (above ~52–54%) increases blood viscosity and thrombosis risk. This is the most common adverse effect managed in TRT clinical practice. Options include: dose reduction, switching to more frequent smaller doses, therapeutic phlebotomy (blood donation), and in some cases switching to transdermal formulations. [Source: Bachman E et al., 2014 — Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin — Annals of Internal Medicine]
HPG Axis Suppression
Exogenous testosterone completely suppresses LH and FSH within days of starting. Testicular atrophy occurs over weeks to months of use. Sperm production is suppressed — most men on TRT cannot conceive without additional treatment (hCG or FSH supplementation to maintain intratesticular testosterone and spermatogenesis).
Men who want to preserve fertility during TRT should discuss hCG supplementation with their prescribing physician. Men who want to conceive naturally should discontinue TRT under medical supervision.
Cardiovascular
At TRT doses in hypogonadal men, the cardiovascular evidence is generally reassuring — multiple studies show neutral or positive cardiovascular effects, as hypogonadism itself is associated with metabolic syndrome and cardiovascular risk. [Source: Corona G et al., 2017 — Cardiovascular risk associated with testosterone-boosting medications — Expert Opinion on Drug Safety]
At supraphysiological doses, the cardiovascular picture worsens: LDL elevation, HDL suppression, LVH, and accelerated atherosclerosis are documented. The Baggish et al. Circulation 2017 paper on long-term AAS users remains the key reference.
Injection Technique: IM vs. Subcutaneous
Testosterone enanthate is licensed for intramuscular injection. However, subcutaneous injection (into fat tissue, typically abdomen or outer thigh) is widely used in TRT settings with:
- No meaningful difference in bioavailability [Source: Spratt DI et al., 2021 — A randomised crossover study comparing subcutaneous and intramuscular testosterone enanthate — Journal of Clinical Endocrinology & Metabolism]
- Lower injection volume required
- Less injection site discomfort for many patients
- More consistent absorption with twice-weekly vs. once-weekly dosing
UK private TRT clinics increasingly use subcutaneous injection as standard. NHS prescriptions typically specify IM, but the clinical evidence for subQ equivalence is strong.
Monitoring Protocol
At baseline before starting:
- Total testosterone, LH, FSH, oestradiol, SHBG, prolactin
- PSA (men over 40)
- Full blood count and haematocrit
- Lipid panel
- Liver function tests
- Blood pressure
At 6–8 weeks (first steady state):
- Total testosterone (trough and peak if possible)
- Oestradiol (symptom-guided management)
- Haematocrit
- Blood pressure
Every 3–6 months (stable TRT):
- Total testosterone, haematocrit, PSA, blood pressure
- Annual: full lipid panel, liver function, full blood count
The Short Version
Testosterone enanthate is the reference testosterone — the compound against which every other androgen is pharmacologically measured. At therapeutic replacement doses, it has one of the most evidence-backed safety and efficacy profiles in endocrinology. The T Trials, Bhasin dose-response data, and decades of clinical use establish it clearly. Side effects at TRT doses — haematocrit elevation, oestrogen management, androgenic effects — are manageable with appropriate monitoring. At supraphysiological doses, the risk profile increases significantly and proportionally. For men with confirmed hypogonadism seeking the best-evidenced injectable testosterone option: enanthate and cypionate are clinically equivalent, both excellent choices, and both available through UK private TRT clinics.
Key references: Bhasin S et al., American Journal of Physiology, 2001; Finkelstein JS et al., NEJM, 2013; Snyder PJ et al., NEJM, 2016; Bachman E et al., Annals of Internal Medicine, 2014; Baggish AL et al., Circulation, 2017; Spratt DI et al., JCEM, 2021; Morgentaler A et al., Endocrine Practice, 2015.